A Study on the Efficacy of Disitamab Vedotin in Advanced HER2-positive Paget's Disease.
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This study is a single-center, phase II clinical trial. Patients with HER2-positive advanced breast and extramammary Paget's disease who met the eligibility criteria were enrolled after signing an informed consent form. All patients received treatment with 2mg/kg of trastuzumab deruxtecan intravenous infusion every 3 weeks until disease progression. Follow-up was conducted until disease progression, withdrawal of informed consent by the subject, loss to follow-up, or death. Clinical tumor imaging assessments were performed using RECIST during the treatment process.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Osoby pełnoletnie (powyżej 18 lat).
- •Potwierdzona diagnoza raka Pageta (skóry lub poza skórą) z wynikiem dodatnim na HER2.
- •Stan ogólny pozwalający na aktywność (ECOG 0-1).
- •Choroba, którą można zmierzyć na obrazach (np. tomografia komputerowa).
- •Dobre wyniki badań krwi wskazujące na prawidłowe działanie narządów (wątroba, nerki, krzepnięcie).
- •Przewidywany czas życia co najmniej 3 miesiące.
✗ Disqualifies
- •Problemy z układem odpornościowym (np. HIV, po przeszczepach).
- •Aktywne choroby autoimmunologiczne w ciągu ostatnich 2 lat.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 75 Years
- Last updated (source)
- December 17, 2024
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Fudan University Shanghai Cancer Center
Shanghai, China
Trial contact
wang hongxia, PHD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.